{
  "citations": [
    {
      "id": 15126562,
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.",
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/34782755",
      "authors": [
        "Brouwer Jurriaan M J L",
        "Nijenhuis Marga",
        "Soree Bianca",
        "Guchelaar Henk-Jan",
        "Swen Jesse J",
        "van Schaik Ron H N",
        "Weide Jan van der",
        "Rongen Gerard A P J M",
        "Buunk Anne-Marie",
        "de Boer-Veger Nienke J",
        "Houwink Elisa J F",
        "van Westrhenen Roos",
        "Wilffert Bob",
        "Deneer Vera H M",
        "Mulder Hans"
      ],
      "crossReferences": [
        {
          "id": 1451632760,
          "resource": "PubMed",
          "resourceId": "34782755",
          "_url": "https://www.ncbi.nlm.nih.gov/pubmed/34782755",
          "version": 0
        },
        {
          "id": 1451632761,
          "resource": "DOI",
          "resourceId": "10.1038/s41431-021-01004-7",
          "_url": "http://dx.doi.org/10.1038%2Fs41431-021-01004-7",
          "version": 0
        }
      ],
      "hasKeyword": true,
      "journal": "European journal of human genetics : EJHG",
      "meshDiseases": [
        "PA165108622"
      ],
      "meshTerms": [
        "Antidepressive Agents",
        "Citalopram",
        "Cytochrome P-450 CYP2C19",
        "Cytochrome P-450 CYP2D6",
        "Drug Interactions",
        "Humans",
        "Paroxetine",
        "Pharmacogenetics",
        "Serotonin Uptake Inhibitors",
        "Sertraline"
      ],
      "month": 10,
      "nonHuman": false,
      "objCls": "Literature",
      "page": "1114-1120",
      "pediatric": false,
      "pgkbPublication": false,
      "pubDate": "2022-10-01T00:00:00-07:00",
      "summary": "The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here, presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and antidepressants of the selective serotonin reuptake inhibitor type (SSRIs). Both genes' genotypes are translated into predicted normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), or ultra-rapid metabolizer (UM). Evidence-based dose recommendations were obtained, based on a structured analysis of published literature. In CYP2C19 PM patients, escitalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 75% of the normal maximum dose. Escitalopram should be avoided in UM patients. In CYP2C19 PM patients, citalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 70% (65-75%) of the normal maximum dose. In contrast to escitalopram, no action is needed for CYP2C19 UM patients. In CYP2C19 PM patients, sertraline dose should not exceed 37.5% of the normal maximum dose. No action is needed for CYP2C19 IM and UM patients. In CYP2D6 UM patients, paroxetine should be avoided. No action is needed for CYP2D6 PM and IM patients. In addition, no action is needed for the other gene-drug combinations. Clinical effects (increase in adverse events or decrease in efficacy) were lacking for these other gene-drug combinations. DPWG classifies CYP2C19 genotyping before the start of escitalopram, citalopram, and sertraline, and CYP2D6 genotyping before the start of paroxetine as \"potentially beneficial\" for toxicity/effectivity predictions. This indicates that genotyping prior to treatment can be considered on an individual patient basis.",
      "terms": [
        {"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}
      ],
      "version": 2,
      "volume": "30",
      "year": 2022
    },
    {
      "id": 7283333,
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "crossReferences": [
        {
          "id": 769250885,
          "resource": "PubMed",
          "resourceId": "21412232",
          "_url": "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
          "version": 0
        },
        {
          "id": 1449247827,
          "resource": "DOI",
          "resourceId": "10.1038/clpt.2011.34",
          "_url": "http://dx.doi.org/10.1038%2Fclpt.2011.34",
          "version": 0
        }
      ],
      "hasKeyword": true,
      "journal": "Clinical pharmacology and therapeutics",
      "meshDiseases": [],
      "meshTerms": [
        "Animals",
        "Aryl Hydrocarbon Hydroxylases",
        "Cytochrome P-450 CYP2C9",
        "Drug Administration Schedule",
        "Drug-Related Side Effects and Adverse Reactions",
        "Humans",
        "Pharmaceutical Preparations",
        "Pharmacogenetics",
        "Practice Guidelines as Topic"
      ],
      "month": 5,
      "nonHuman": false,
      "objCls": "Literature",
      "page": "662-73",
      "pediatric": false,
      "pgkbPublication": false,
      "pubDate": "2011-05-01T00:00:00-07:00",
      "summary": "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
      "terms": [],
      "version": 2,
      "volume": "89",
      "year": 2011
    }
  ],
  "guideline": {
    "objCls": "Guideline Annotation",
    "id": "PA166104980",
    "name": "Annotation of DPWG Guideline for sertraline and CYP2C19",
    "alternateDrugAvailable": false,
    "cancerGenome": false,
    "crossReferences": [],
    "dosingInformation": false,
    "guidelineGenes": [
      {
        "id": 1451417440,
        "alleles": [
          {
            "id": 1451417441,
            "_label": "*1",
            "function": {
              "id": 1445558335,
              "parents": [],
              "resource": "Allele Function",
              "term": "Normal function",
              "termId": "haplotypeTags:1445558335",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165980634",
              "symbol": "CYP2C19*1",
              "name": "*1",
              "version": 25
            },
            "version": 0
          },
          {
            "id": 1451417442,
            "_label": "*2",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165980635",
              "symbol": "CYP2C19*2",
              "name": "*2",
              "version": 25
            },
            "version": 0
          },
          {
            "id": 1451417443,
            "_label": "*3",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165980636",
              "symbol": "CYP2C19*3",
              "name": "*3",
              "version": 25
            },
            "version": 0
          },
          {
            "id": 1451417444,
            "_label": "*4",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165980637",
              "symbol": "CYP2C19*4",
              "name": "*4",
              "version": 25
            },
            "version": 0
          },
          {
            "id": 1451417445,
            "_label": "*5",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165980638",
              "symbol": "CYP2C19*5",
              "name": "*5",
              "version": 25
            },
            "version": 0
          },
          {
            "id": 1451417446,
            "_label": "*6",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816522",
              "symbol": "CYP2C19*6",
              "name": "*6",
              "version": 27
            },
            "version": 0
          },
          {
            "id": 1451417447,
            "_label": "*7",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816523",
              "symbol": "CYP2C19*7",
              "name": "*7",
              "version": 27
            },
            "version": 0
          },
          {
            "id": 1451417448,
            "_label": "*8",
            "function": {
              "id": 1445558515,
              "parents": [],
              "resource": "Allele Function",
              "term": "No function",
              "termId": "haplotypeTags:1445558515",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816524",
              "symbol": "CYP2C19*8",
              "name": "*8",
              "version": 27
            },
            "version": 0
          },
          {
            "id": 1451417449,
            "_label": "*9",
            "function": {
              "id": 1445558331,
              "parents": [],
              "resource": "Allele Function",
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816525",
              "symbol": "CYP2C19*9",
              "name": "*9",
              "version": 27
            },
            "version": 0
          },
          {
            "id": 1451417450,
            "_label": "*10",
            "function": {
              "id": 1445558331,
              "parents": [],
              "resource": "Allele Function",
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816526",
              "symbol": "CYP2C19*10",
              "name": "*10",
              "version": 27
            },
            "version": 0
          },
          {
            "id": 1451417451,
            "_label": "*17",
            "function": {
              "id": 1445558332,
              "parents": [],
              "resource": "Allele Function",
              "term": "Increased function",
              "termId": "haplotypeTags:1445558332",
              "version": 1
            },
            "haplotype": {
              "objCls": "Haplotype",
              "id": "PA165816533",
              "symbol": "CYP2C19*17",
              "name": "*17",
              "version": 29
            },
            "version": 0
          }
        ],
        "gene": {
          "objCls": "Gene",
          "id": "PA124",
          "symbol": "CYP2C19",
          "name": "cytochrome P450 family 2 subfamily C member 19",
          "alleleFile": "CYP2C19_allele_definition_table.xlsx",
          "altNames": {
            "synonym": [
              "cytochrome P450, family 2, subfamily C, polypeptide 19"
            ],
            "symbol": [
              "CPCJ",
              "CYP2C",
              "P450IIC19"
            ]
          },
          "buildVersion": "GRCh38.p7",
          "cbStart": "q23.33",
          "cbStop": "q23.33",
          "chr": {
            "objCls": "Chromosome",
            "id": "PA504",
            "name": "chr10",
            "version": 3
          },
          "chrStartPosB37": 96522463,
          "chrStartPosB38": 94762681,
          "chrStopPosB37": 96612671,
          "chrStopPosB38": 94853205,
          "cpicGene": true,
          "crossReferences": [
            {
              "id": 553242512,
              "resource": "Comparative Toxicogenomics Database",
              "resourceId": "1557",
              "_url": "http://ctdbase.org/detail.go?type=gene&acc=1557",
              "version": 0
            },
            {
              "id": 132256028,
              "resource": "Ensembl",
              "resourceId": "ENSG00000165841",
              "_url": "https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165841",
              "version": 0
            },
            {
              "id": 73372,
              "resource": "GenAtlas",
              "resourceId": "CYP2C19",
              "_url": "http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=CYP2C19",
              "version": 1
            },
            {
              "id": 88300,
              "resource": "GeneCard",
              "resourceId": "CYP2C19",
              "_url": "https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP2C19",
              "version": 1
            },
            {
              "id": 608081307,
              "resource": "HGNC",
              "resourceId": "HGNC:2621",
              "_url": "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC%3A2621",
              "version": 1
            },
            {
              "id": 608081309,
              "resource": "HumanCyc Gene",
              "resourceId": "HS09293",
              "_url": "http://biocyc.org/HUMAN/NEW-IMAGE?object=HS09293",
              "version": 0
            },
            {
              "id": 560874113,
              "resource": "ModBase",
              "resourceId": "P33261",
              "_url": "http://salilab.org/modbase/search?modelflag=longest&databaseID=P33261",
              "version": 0
            },
            {
              "id": 455910,
              "resource": "MutDB",
              "resourceId": "CYP2C19",
              "_url": "http://www.mutdb.org/genes/search?_method=POST&data%5BSearch%5D%5Bidentifier%5D=CYP2C19",
              "version": 1
            },
            {
              "id": 10744,
              "resource": "NCBI Gene",
              "resourceId": "1557",
              "_url": "https://www.ncbi.nlm.nih.gov/gene/1557",
              "version": 1
            },
            {
              "id": 716,
              "resource": "OMIM",
              "resourceId": "124020",
              "_url": "https://omim.org/entry/124020",
              "version": 1
            },
            {
              "id": 560556306,
              "resource": "OMIM",
              "resourceId": "609535",
              "_url": "https://omim.org/entry/609535",
              "version": 0
            },
            {
              "id": 1451280335,
              "resource": "PharmVar Gene",
              "resourceId": "CYP2C19",
              "_url": "https://www.pharmvar.org/gene/CYP2C19",
              "version": 0
            },
            {
              "id": 560556305,
              "resource": "RefSeq DNA",
              "resourceId": "NG_008384",
              "_url": "https://www.ncbi.nlm.nih.gov/nuccore/NG_008384",
              "version": 0
            },
            {
              "id": 37037,
              "resource": "RefSeq DNA",
              "resourceId": "NT_030059",
              "_url": "https://www.ncbi.nlm.nih.gov/nuccore/NT_030059",
              "version": 1
            },
            {
              "id": 37896,
              "resource": "RefSeq Protein",
              "resourceId": "NP_000760",
              "_url": "https://www.ncbi.nlm.nih.gov/nuccore/NP_000760",
              "version": 1
            },
            {
              "id": 46971,
              "resource": "RefSeq RNA",
              "resourceId": "NM_000769",
              "_url": "https://www.ncbi.nlm.nih.gov/nuccore/NM_000769",
              "version": 1
            },
            {
              "id": 122288,
              "resource": "UCSC Genome Browser",
              "resourceId": "NM_000769",
              "_url": "https://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_000769",
              "version": 1
            },
            {
              "id": 62333091,
              "name": "CP2CJ_HUMAN",
              "resource": "UniProtKB",
              "resourceId": "P33261",
              "_url": "https://www.uniprot.org/uniprot/P33261",
              "version": 1
            },
            {
              "id": 88,
              "resource": "URL",
              "resourceId": "http://www.imm.ki.se/CYPalleles/cyp2c19.htm",
              "_url": "http://www.imm.ki.se/CYPalleles/cyp2c19.htm",
              "version": 1
            }
          ],
          "hasNonStandardHaplotypes": false,
          "hideHaplotypes": false,
          "pharmVarGene": true,
          "strand": "plus",
          "terms": [
            {"id":560498878,"_url":"http://amigo.geneontology.org/amigo/term/GO:0004497","resource":"Gene Ontology","term":"monooxygenase activity","termId":"GO:0004497"},
            {"id":560500134,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005783","resource":"Gene Ontology","term":"endoplasmic reticulum","termId":"GO:0005783"},
            {"id":560500141,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005789","resource":"Gene Ontology","term":"endoplasmic reticulum membrane","termId":"GO:0005789"},
            {"id":560500144,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005792","resource":"Gene Ontology","term":"microsome","termId":"GO:0005792"},
            {"id":560501294,"_url":"http://amigo.geneontology.org/amigo/term/GO:0008202","resource":"Gene Ontology","term":"steroid metabolic process","termId":"GO:0008202"},
            {"id":560496176,"_url":"http://amigo.geneontology.org/amigo/term/GO:0008395","resource":"Gene Ontology","term":"steroid hydroxylase activity","termId":"GO:0008395"},
            {"id":560503412,"_url":"http://amigo.geneontology.org/amigo/term/GO:0009055","resource":"Gene Ontology","term":"electron carrier activity","termId":"GO:0009055"},
            {"id":560499972,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016020","resource":"Gene Ontology","term":"membrane","termId":"GO:0016020"},
            {"id":560506711,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016098","resource":"Gene Ontology","term":"monoterpenoid metabolic process","termId":"GO:0016098"},
            {"id":560495264,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016491","resource":"Gene Ontology","term":"oxidoreductase activity","termId":"GO:0016491"},
            {"id":560507281,"_url":"http://amigo.geneontology.org/amigo/term/GO:0017144","resource":"Gene Ontology","term":"drug metabolic process","termId":"GO:0017144"},
            {"id":560508105,"_url":"http://amigo.geneontology.org/amigo/term/GO:0018675","resource":"Gene Ontology","term":"(S)-limonene 6-monooxygenase activity","termId":"GO:0018675"},
            {"id":560508106,"_url":"http://amigo.geneontology.org/amigo/term/GO:0018676","resource":"Gene Ontology","term":"(S)-limonene 7-monooxygenase activity","termId":"GO:0018676"},
            {"id":560509226,"_url":"http://amigo.geneontology.org/amigo/term/GO:0019825","resource":"Gene Ontology","term":"oxygen binding","termId":"GO:0019825"},
            {"id":560496866,"_url":"http://amigo.geneontology.org/amigo/term/GO:0019899","resource":"Gene Ontology","term":"enzyme binding","termId":"GO:0019899"},
            {"id":560509358,"_url":"http://amigo.geneontology.org/amigo/term/GO:0020037","resource":"Gene Ontology","term":"heme binding","termId":"GO:0020037"},
            {"id":560513624,"_url":"http://amigo.geneontology.org/amigo/term/GO:0033767","resource":"Gene Ontology","term":"4-hydroxyacetophenone monooxygenase activity","termId":"GO:0033767"},
            {"id":560515690,"_url":"http://amigo.geneontology.org/amigo/term/GO:0042738","resource":"Gene Ontology","term":"exogenous drug catabolic process","termId":"GO:0042738"},
            {"id":560495388,"_url":"http://amigo.geneontology.org/amigo/term/GO:0046483","resource":"Gene Ontology","term":"heterocycle metabolic process","termId":"GO:0046483"},
            {"id":560495445,"_url":"http://amigo.geneontology.org/amigo/term/GO:0046872","resource":"Gene Ontology","term":"metal ion binding","termId":"GO:0046872"},
            {"id":560509993,"_url":"http://amigo.geneontology.org/amigo/term/GO:0055114","resource":"Gene Ontology","term":"oxidation reduction","termId":"GO:0055114"}
          ],
          "version": 7209
        },
        "version": 0
      }
    ],
    "hasTestingInfo": true,
    "history": [
      {
        "id": 1183704529,
        "date": "2011-08-10T00:00:00-07:00",
        "type": "Create",
        "version": 0
      },
      {
        "id": 1450415055,
        "date": "2019-05-23T15:21:18.200-07:00",
        "description": "Annotation current with November 2018 DPWG Guideline release",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1450821032,
        "date": "2019-10-07T18:31:05.298-07:00",
        "description": "No changes based on August 2019 guideline",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1450956354,
        "date": "2020-01-31T13:48:08.133-08:00",
        "description": "Updated link to 2011 DPWG methods",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1450963901,
        "date": "2020-02-11T07:51:58.173-08:00",
        "description": "Fixed links to 2018 guideline pdfs.",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451417566,
        "date": "2021-04-22T00:00:00-07:00",
        "description": "Added extended dosing",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451632881,
        "date": "2022-01-03T15:05:48.083-08:00",
        "description": "Added DPWG SSRI guideline publication.",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451704218,
        "date": "2022-03-03T16:33:29.790-08:00",
        "description": "Annotation current with May 2021 DPWG Guideline release",
        "type": "Note",
        "version": 0
      },
      {
        "id": 1451707500,
        "date": "2022-03-08T10:42:12.830-08:00",
        "description": "Added information about preemptive genotyping",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451732858,
        "date": "2022-03-28T09:57:43.636-07:00",
        "description": "Annotation current with February 2022 DPWG guideline release",
        "type": "Note",
        "version": 0
      },
      {
        "id": 1451733452,
        "date": "2022-03-28T15:02:06.405-07:00",
        "description": "Updated link to testing guidance page",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451741527,
        "date": "2022-04-05T11:18:43.803-07:00",
        "description": "Added testing guidance tag",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451884692,
        "date": "2022-09-16T14:39:06.937-07:00",
        "description": "Fixed link to gene information document and added explanatory note",
        "type": "Update",
        "version": 0
      }
    ],
    "literature": [
      {"id":15126562,"title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/34782755","crossReferences":[{"id":1451632760,"resource":"PubMed","resourceId":"34782755","_url":"https://www.ncbi.nlm.nih.gov/pubmed/34782755"},{"id":1451632761,"resource":"DOI","resourceId":"10.1038/s41431-021-01004-7","_url":"http://dx.doi.org/10.1038%2Fs41431-021-01004-7"}],"objCls":"Literature","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}]},
      {"id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature","terms":[]},
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[]},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[]}
    ],
    "pediatric": false,
    "recommendation": true,
    "relatedAlleles": [],
    "relatedChemicals": [
      {
        "objCls": "Chemical",
        "id": "PA451333",
        "name": "sertraline",
        "version": 12
      }
    ],
    "relatedGenes": [
      {
        "objCls": "Gene",
        "id": "PA124",
        "symbol": "CYP2C19",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "version": 7209
      }
    ],
    "source": "DPWG",
    "summaryMarkdown": {
      "id": 1447981948,
      "html": "<p>Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.</p>\n",
      "version": 1
    },
    "terms": [],
    "textMarkdown": {
      "id": 1447981947,
      "html": "<p><em><strong>IMPORTANT: As of March 2022, gene information documents from the DPWG are no longer publicly available from the KNMP website. PharmGKB is currently providing PDF versions of these documents to users. These files were downloaded in February 2022. As such, we cannot guarantee that these documents match the mappings DPWG may use internally as there have been no publicly accessible updates since February 2022.</strong></em></p>\n<h3 id=\"dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-between-cyp2c19-and-cyp2d6-and-ssris-european-journal-of-human-genetics-2021\">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European journal of human genetics (2021)</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the November 2018 update and further details on the assessed literature [Article:<a href=\"/pmid/34782755\">34782755</a>].</p>\n<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on CYP2C19 genotype. Patients with CYP2C19 poor metabolizer genotypes should not receive doses exceeding 75 mg/day, and dose should be guided by response and side effects and/or sertraline plasma concentration. No action is recommended for CYP2C19 intermediate or ultrarapid metabolizers.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2C19 PM</td>\n<td>sertraline</td>\n<td>The risk of side effects is increased. The gene variation leads to increased plasma concentrations of sertraline.</td>\n<td>Do not give doses exceeding 75 mg/day. Guide the dose by response and side effects and/or sertraline plasma concentration.</td>\n</tr>\n<tr>\n<td>CYP2C19 IM</td>\n<td>sertraline</td>\n<td>NO action is needed for this gene-drug interaction.</td>\n<td>The gene variation has a minor effect on the sertraline plasma concentration. No effect on side effects was found.</td>\n</tr>\n<tr>\n<td>CYP2C19 UM</td>\n<td>sertraline</td>\n<td>NO action is needed for this gene-drug interaction.</td>\n<td>The gene variation has a negligible effect on the plasma concentration of sertraline. Moreover, no significant effect on response and side effects has been found.</td>\n</tr>\n</tbody>\n</table>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0002008.PDF\" target=\"_blank\">DPWG risk analysis document</a> for sertraline and CYP2C19:</p>\n<blockquote class=\"blockquote\">\n<p>The Dutch Pharmacogenetics Working Group considers genotyping before starting sertraline to be potentially beneficial. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the Dutch Pharmacogenetics Working Group recommends adhering to the gene-drug guideline.</p>\n</blockquote>\n<p><a href=\"/page/testingGuidance\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0002008.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a download=\"CYP2C19.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CYP2C19.pdf\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on <em>CYP2C19</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype (Genotype)</th>\n<th>Therapeutic Dose Recommendation</th>\n<th>Level of Evidence</th>\n<th>Clinical Relevance</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td>\n<td>Reduce dose by 50%.</td>\n<td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td>\n<td>Clinical effect (statistically significant difference): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; adverse drug events resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); international normalized ratio 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l</td>\n</tr>\n<tr>\n<td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td>\n<td>Insufficient data to allow calculation of dose adjustment. Be extra alert to adverse drug events (e.g., nausea, vomiting, diarrhea).</td>\n<td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td>\n<td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5; Kinetic effect (statistically significant difference)</td>\n</tr>\n<tr>\n<td><em>CYP2C19</em> UM (*17/*17)</td>\n<td>None</td>\n<td>no data was retrieved with the literature search</td>\n<td>no data was retrieved with the literature search</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;moderate&quot; quality.</li>\n<li>Please see attached PDF for detailed information about the evaluated studies: <a download=\"sertraline_CYP2C19_271111.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/sertraline_CYP2C19_271111.pdf\">Sertraline CYP2C19 </a></li>\n</ul>\n",
      "version": 16
    },
    "userId": "carrillo",
    "version": 30
  }
}